Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials
Abstract
BACKGROUND: Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference for follow-up research.
METHODS: Researchers comprehensively searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomised controlled trials published up to Mar 28, 2025, with "Imipenem/Cilastatin/Relebactam" or "IMI/CS/REL" as keywords, and screened the results according to the proposed exclusion and inclusion criteria. Data extraction was performed on the included randomized controlled trials (RCTs), while the day 28/30 all-cause mortality, clinical response rate, microbiological response rate, the adverse event response rate and drug-related adverse reaction rate were evaluated using R (4.4.3). The evaluation results were expressed in terms of relative risk with 95% confidence limit (RR, 95%CI).
RESULTS: Six RCTs (1606 subjects) were involved in this meta-analysis. The meta-analysis showed no significant differences between IMI/CS/REL and comparators in day 28/30 all-cause mortality (RR = 0.82, 95% CI 0.39-1.72, P = 0.10), in clinical response rate during the early follow-up period (EFU) (RR = 1.02, 95%CI 0.96-1.08, P = 0.67) and in microbiological response at EFU (RR = 1.02, 95%CI 0.95-1.09, P = 0.76). The adverse events (AEs) rate also showed no statistical…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,606 participants or records.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.